In particular, it can be a change in the secondary or tertiary structure of proteins, including as a result of mutations in their amino acid sequence (for example, ALys amyloidosis) or their synthesis in abnormal malignant cells (for example, AL-amyloidosis); accumulation of high concentrations of protein in the body, including as a result of medical procedures (for example, DRA, Insulin-derived amyloidosis), etc., which increases proteins’ tendency to aggregate with the formation of amyloid fibrils. The gene discussed is INS; the disease is AL amyloidosis.